-+ 0.00%
-+ 0.00%
-+ 0.00%

VIKING THERAPEUTICS ANNOUNCES INITIATION OF VK2735 ORAL PHASE 3 CLINICAL PROGRAM IN PATIENTS WITH OBESITY

Reuters·10/14/2026 11:07:16